Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Israel / NCT00445367
Active, not recruiting Observational

Biobank For MS And Other Demyelinating Diseases

NCT00445367 · tracked via the Priya Life Science Israel tracker
Sponsor
Accelerated Cure Project for Multiple Sclerosis
Phase
Observational
Started
2006-05
Last updated
2025-10-02

Condition(s) studied

Multiple SclerosisTransverse MyelitisNeuromyelitis OpticaAcute Disseminated EncephalomyelitisOptic Neuritis

Study summary

To establish a large, longitudinal collection of high quality samples and data from subjects with MS, selected other demyelinating diseases (Transverse Myelitis (TM), Neuromyelitis Optica (NMO) or Devic's, Acute Disseminated Encephalomyelitis (ADEM), and Optic Neuritis (ON)), and related and unrelated unaffected controls. Samples and data will be available as a shared resource to scientists researching the causes, sub-types, and biomarkers of MS and related demyelinating diseases.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * age 18+ able to give informed consent or individuals younger than 18 with parental permission and able to give assent * willing to provide up to 110 ml (50 ml for \< 18 years old) of blood via venipuncture * experienced at least one CNS demyelinating event characteristic of MS, TM, NMO, ADEM, or ON Exclusion Criteria: * history of blood borne pathogens * allogeneic bone marrow transplant * clinical or radiological evidence of stroke, meningitis, or other well characterized diseases of the nervous system (with the exception of MS, TM, NMO, ADEM, or ON). * weight less than 37 pounds

Trial sites (10)

FacilityCityRegionStatus
Barrow Neurological Institute Phoenix Arizona
Stanford University Stanford California
The Rocky Mountain MS Center at Anschutz Medical Campus at UC Denver Aurora Colorado
Shepherd Center Atlanta Georgia
Johns Hopkins Baltimore Maryland
Beth Israel Deaconess Boston Massachusetts
University of Massachusetts Medical School Worcester Massachusetts
Multiple Sclerosis Research Center of New York New York New York
The Ohio State University Columbus Ohio
University of Texas Southwestern Medical Center at Dallas Dallas Texas

Other trials for the same condition

A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis Active, not recruiting
The Effect of a Mediterranean Diet on Quality of Life in Multiple Sclerosis Patients Recruiting
Implementation of an Advanced Telerehabilitation Solution for People With Multiple Sclerosis Starting soon
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis Active, not recruiting
Prevalence and Impact of Obstructive Sleep Apnea in Multiple Sclerosis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT00445367 on ClinicalTrials.gov ↗ ← All trials in Israel